Natco Pharma Ltd (NSE:NATCOPHARM)
₹ 1196.15 -4.5 (-0.37%) Market Cap: 214.17 Bil Enterprise Value: 199.39 Bil PE Ratio: 15.54 PB Ratio: 3.68 GF Score: 82/100

Q3 2024 Natco Pharma Ltd Earnings Call Transcript

Feb 15, 2024 / 05:30AM GMT
Release Date Price: ₹887.1 (+0.26%)
Operator

Ladies and gentlemen, good day, and welcome to the Natco Pharma Q3 FY24 post-results earnings conference call hosted by Batlivala & Karani Securities India Private Limited. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Hrishikesh Patole from B&K Securities India Private Limited. And over to you, sir.

Hrishikesh Patole
Batlivala & Karani Securities India Pvt. Ltd. - Analyst

Good morning everyone. On behalf of B&K Securities, I welcome all for FY24 earnings conference call of Natco Pharma.

Rajeev Nannapaneni
Natco Pharma Ltd - Chief Executive Officer, Executive Director

Good morning, everyone. Thank you, Hrishikesh, again, welcome everyone to our conference call discussing our results for the third quarter of FY24, which ended December 31, 2023. Our discussion during this call will include certain forward-looking statements, which are predictions, projections or other estimates about future events.

While these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot